Formulations That Meet Unmet Patient Needs
Focused on long acting
Developing Finished Dosage Forms and a Portfolio of APIs
Fully integrated GMP
Pipeline of Multiple Late Stage Products
In Phase III for RMS and Phase II for
PPMS for treating MS
We are a clinical stage pharmaceutical company, developing complex active pharmaceutical ingredients.
Our main focus is on developing long acting depot injectable drugs.
Our lead programs are GA Depot for treating various forms of MS and long acting Pregabalin (Lyrica®) for pain.
Mapi Pharma and Mylan Strengthen Partnership to Develop and Commercialize Once-Monthly Glatiramer Acetate Depot for Relapsing-Remitting Forms of Multiple Sclerosis
NESS ZIONA, Israel, June 15, 2020 — Mapi Pharma Ltd., a privately held, fully integrated, late clinical stage biopharmaceutical company today announced an additional $20 million investment from Mylan in support of continued Phase 3 clinical study progress to bring to market in the U.S. Glatiramer Acetate (GA) Depot, a proposed once-monthly injection for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).
Mapi Announces First Patient Enrolled in the Phase III Clinical Trial of GA Depot for Relapsing Multiple Sclerosis (RMS)
Mapi Pharma Ltd. announced today that the first patient has been enrolled in its Phase III study with GA Depot for relapsing forms of multiple sclerosis (RMS). Glatiramer acetate, the active material of Copaxone®, or its generic forms, is the most common treatment for RMS in the US. GA Depot is a long-acting depot formulation injection of glatiramer acetate administered once every four weeks, compared with the daily or thrice weekly regimen used with Copaxone® or its generic forms…